Head-to-head evidence
ALZ-101 vs CM383
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALZ-101
Developed by Alzinova AB
NCT05328115 · Phase 1 · completed
Most of the trial was randomized and blinded against placebo, but the highest-dose group was given openly rather than blinded, and only 33 people took part. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reports Part A of the trial (26 randomised participants), fewer than the trial's registered enrollment of 33.
CM383
Developed by Keymed Biosciences
NCT06412185 · Phase 1 · status unknown
This is a randomized, blinded, placebo-controlled study, but it is an early safety study in healthy volunteers rather than patients, and its primary measured outcome is safety rather than a disease outcome. Results have not yet been posted.
Next expected readout: December 2026 · NCT06619613 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALZ-101's landscape · CM383's landscape